search
Back to results

Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)

Primary Purpose

ADHD, ADD

Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Calanus oil
Medical Paraffin
Sponsored by
University Hospital of North Norway
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ADHD focused on measuring ADHD, omega 3, children, nutrition, MUFA, ADD, PUFA, Calanus, learning difficulties

Eligibility Criteria

6 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- ADHD or ADD according to DSM-IV criteria

Exclusion Criteria:

  • IQ below 70
  • infantil autism, psychosis, bipolar disorders and serious somatic disease
  • any abnormal or pathological blood test during trial
  • Omega-3 supplement taken until 3 months before inclusion

Sites / Locations

  • Finnmarkssykehuset SANKS BUP KarasjokRecruiting
  • University Hospital of North NorwayRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Calanus oil

Placebo

Arm Description

Children receiving omega-3 in form om calanus oil in capsule form

Children receiving medical paraffin in capsule form (2 ml volume per day)

Outcomes

Primary Outcome Measures

ADHD rating scale by Russel Barkley
Reduction in symptom score

Secondary Outcome Measures

BRIEF - Behavior Rating Inventory of Executive Function
Reduction in symptom score
SNAP-IV The Swanson Nolan and Pelham-IV Questionnaire
Change
ARI - Affective Reactivity Index - a scale that contains six symptom items and one impairment item about irritability
Reduction in symptoms
TOVA CPT - Continuous Performance test - a task-oriented computerized assessment of attention-related problems in individuals aged 8 years and older
Change
SDQ - Strength and Difficulty Questionnaire
Psychological screening tool used to assess the behavioral and emotional strengths and difficulties of children and adolescents, consisting of 25 items across five dimensions
Kid-Screen-52
52 items examining Health-related Quality of Life

Full Information

First Posted
January 8, 2016
Last Updated
July 31, 2023
Sponsor
University Hospital of North Norway
search

1. Study Identification

Unique Protocol Identification Number
NCT02986672
Brief Title
Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)
Official Title
ADHD and Nutrition: The Influence of Omega-3 on ADHD Related Symptoms
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 3, 2017 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital of North Norway

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aim to evaluate the effect of marine monounsaturated and polyunsaturated fatty acids on children aged from 6-16 years, with ADHD/ADD and related symptoms. The study is a randomized, double-blind placebo-control study including approximately 330 children from Norway. The primary outcome measure is ADHD core symptoms reported by caregivers, teachers and the child at 0 months (baseline), 6 months (end of treatment) and 12 months (6 months post treatment). The secondary outcome measures are reading and writing disabilities, cognitive functions, and physical Health.
Detailed Description
Children with ADHD are shown to have low blood levels of omega-3 fatty acids, not related to diet. Low levels of omega-3 has also been directly related to poor cognition and behavior. Trials have shown that supplement with omega-3 may improve literacy and behavior in children with ADHD symptoms. It has also been shown to improve both memory and reaction time. The effect sizes found in meta analysis of placebo- controlled clinical trials on ADHD core symptoms are small to modest. In a study of adolescent mental health in North Norway in 2003-2005 a significant association was found between intake of fish and hyperactivity as adolescents with a high intake showed less hyperactivity than peers with a low intake (unpublished results from The Norwegian Arctic Adolescent Health Study, Siv Kvernmo). There are several key limitations to the existing studies. Underpowered sample size, different methodology and short intervention periods are some factors raising the question of effect size. Other trials have no control group. We are designing this study taking these limitations into consideration. In addition we are using whole marine oil from the zooplankton Calanus finmarchicus that has a high natural content of stearidonic acid 18:3 n-3 that is a precursor to EPA. The oil also has a high content of astaxanthines - a natural antioxidant. Earlier clinical studies have not used pure oil from zooplankton such as Calanus finmarchicus. The oil is not processed chemically such as ethylation, that not only alter the structure of the oil, but also devoid the product of its natural antioxidants. Blood tests are taken before and after a 6 month intervention period. These blood tests entail both omega-3 index analysis as well as general hematology and biochemistry.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ADHD, ADD
Keywords
ADHD, omega 3, children, nutrition, MUFA, ADD, PUFA, Calanus, learning difficulties

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
330 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Calanus oil
Arm Type
Active Comparator
Arm Description
Children receiving omega-3 in form om calanus oil in capsule form
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Children receiving medical paraffin in capsule form (2 ml volume per day)
Intervention Type
Dietary Supplement
Intervention Name(s)
Calanus oil
Intervention Description
Omega-3 oil in form of calanus oil
Intervention Type
Other
Intervention Name(s)
Medical Paraffin
Intervention Description
2ml per day
Primary Outcome Measure Information:
Title
ADHD rating scale by Russel Barkley
Description
Reduction in symptom score
Time Frame
0, 3, 6, and 12 months
Secondary Outcome Measure Information:
Title
BRIEF - Behavior Rating Inventory of Executive Function
Description
Reduction in symptom score
Time Frame
0, 3, 6, and 12 months
Title
SNAP-IV The Swanson Nolan and Pelham-IV Questionnaire
Description
Change
Time Frame
0, 3, 6, and 12 months
Title
ARI - Affective Reactivity Index - a scale that contains six symptom items and one impairment item about irritability
Description
Reduction in symptoms
Time Frame
0, 3, 6, and 12 months
Title
TOVA CPT - Continuous Performance test - a task-oriented computerized assessment of attention-related problems in individuals aged 8 years and older
Description
Change
Time Frame
0, 3, 6, and 12 months
Title
SDQ - Strength and Difficulty Questionnaire
Description
Psychological screening tool used to assess the behavioral and emotional strengths and difficulties of children and adolescents, consisting of 25 items across five dimensions
Time Frame
0, 3, 6, and 12 months
Title
Kid-Screen-52
Description
52 items examining Health-related Quality of Life
Time Frame
0, 3, 6, and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - ADHD or ADD according to DSM-IV criteria Exclusion Criteria: IQ below 70 infantil autism, psychosis, bipolar disorders and serious somatic disease any abnormal or pathological blood test during trial Omega-3 supplement taken until 3 months before inclusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Judeson R Joseph, MD
Phone
+4777755705
Email
judeson.joseph@unn.no
First Name & Middle Initial & Last Name or Official Title & Degree
Siv E Kvernmo, MD PhD
Phone
+4777755726
Email
siv.kvernmo@uit.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Siv Kvernmo, MD PhD
Organizational Affiliation
University of Tromso
Official's Role
Study Director
Facility Information:
Facility Name
Finnmarkssykehuset SANKS BUP Karasjok
City
Karasjok
State/Province
Finnmark
ZIP/Postal Code
9730
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingunn Eriksen
Phone
+4792281651
Email
ingunn.eriksen@finnmarkssykehuset.no
Facility Name
University Hospital of North Norway
City
Tromsø
State/Province
Troms
ZIP/Postal Code
9038
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judeson R Joseph, MD
Phone
77755705
Email
judeson.joseph@unn.no
First Name & Middle Initial & Last Name & Degree
Siv Kvernmo, Prof MD
Phone
77755725
Email
siv.kvernmo@uit.no

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25146492
Citation
Raine A, Portnoy J, Liu J, Mahoomed T, Hibbeln JR. Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial. J Child Psychol Psychiatry. 2015 May;56(5):509-20. doi: 10.1111/jcpp.12314. Epub 2014 Aug 22.
Results Reference
background
PubMed Identifier
25581035
Citation
Gow RV, Hibbeln JR, Parletta N. Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder. Curr Opin Clin Nutr Metab Care. 2015 Mar;18(2):133-8. doi: 10.1097/MCO.0000000000000140.
Results Reference
background
PubMed Identifier
24934907
Citation
Heilskov Rytter MJ, Andersen LB, Houmann T, Bilenberg N, Hvolby A, Molgaard C, Michaelsen KF, Lauritzen L. Diet in the treatment of ADHD in children - a systematic review of the literature. Nord J Psychiatry. 2015 Jan;69(1):1-18. doi: 10.3109/08039488.2014.921933. Epub 2014 Jun 16.
Results Reference
background
PubMed Identifier
21828168
Citation
Milte CM, Sinn N, Buckley JD, Coates AM, Young RM, Howe PR. Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J Child Health Care. 2011 Dec;15(4):299-311. doi: 10.1177/1367493511403953. Epub 2011 Aug 9.
Results Reference
background
PubMed Identifier
23515006
Citation
Stonehouse W, Conlon CA, Podd J, Hill SR, Minihane AM, Haskell C, Kennedy D. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr. 2013 May;97(5):1134-43. doi: 10.3945/ajcn.112.053371. Epub 2013 Mar 20.
Results Reference
background
PubMed Identifier
16777670
Citation
Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006 Apr;18(2):155-72. doi: 10.1080/09540260600583031.
Results Reference
background
PubMed Identifier
23826114
Citation
Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS One. 2013 Jun 24;8(6):e66697. doi: 10.1371/journal.pone.0066697. Print 2013. Erratum In: PLoS One. 2013;8(9). doi:10.1371/annotation/26c6b13f-b83a-4a3f-978a-c09d8ccf1ae2.
Results Reference
background
PubMed Identifier
24285691
Citation
Hoper AC, Salma W, Sollie SJ, Hafstad AD, Lund J, Khalid AM, Raa J, Aasum E, Larsen TS. Wax esters from the marine copepod Calanus finmarchicus reduce diet-induced obesity and obesity-related metabolic disorders in mice. J Nutr. 2014 Feb;144(2):164-9. doi: 10.3945/jn.113.182501. Epub 2013 Nov 27.
Results Reference
background
PubMed Identifier
22323762
Citation
Eilertsen KE, Maehre HK, Jensen IJ, Devold H, Olsen JO, Lie RK, Brox J, Berg V, Elvevoll EO, Osterud B. A wax ester and astaxanthin-rich extract from the marine copepod Calanus finmarchicus attenuates atherogenesis in female apolipoprotein E-deficient mice. J Nutr. 2012 Mar;142(3):508-12. doi: 10.3945/jn.111.145698. Epub 2012 Feb 8.
Results Reference
background

Learn more about this trial

Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)

We'll reach out to this number within 24 hrs